ReviewDrugs2015
Isavuconazonium: first global approval.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- 1,2,4-Triazolium compounds as anti-oomycete leads against Phytophthora capsici.Pest management science · 2026Article
- Demographic, Clinical, and Mycologic Differences Between Invasive Fungal Sinusitis and Pneumonia in Hematologic Malignancy.Open forum infectious diseases · 2026Article
- A Review of Recent Advances in the Anticancer Mechanisms of Activity of Novel Thiazoles and 4-Thiazolidinones/Thiazolidinediones (2021-2025).Molecules (Basel, Switzerland) · 2026Review
- Design, synthesis, and biological evaluation of 2-phenylthiazole CYP51 inhibitors.RSC medicinal chemistry · 2025Article
- Deep learning-based dipeptidyl peptidase IV inhibitor screening, experimental validation, and GaMD/LiGaMD analysis.BMC biology · 2025Article
- Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Identification of lurasidone as a potent inhibitor of severe fever with thrombocytopenia syndrome virus by targeting the viral nucleoprotein.Frontiers in microbiology · 2025Article
- Unexpected renal influence on isavuconazole trough concentrations: two case reports and literature review.Frontiers in medicine · 2025Article
- Chirality of New Drug Approvals (2013-2022): Trends and Perspectives.Journal of medicinal chemistry · 2024Review
- Repurposing Benzimidazoles against Causative Agents of Chromoblastomycosis: Albendazole Has Superior In Vitro Activity Than Mebendazole and Thiabendazole.Journal of fungi (Basel, Switzerland) · 2023Article
- Striking Back against Fungal Infections: The Utilization of Nanosystems for Antifungal Strategies.International journal of molecular sciences · 2021Review
- The antifungal drug isavuconazole inhibits the replication of human cytomegalovirus (HCMV) and acts synergistically with anti-HCMV drugs.Antiviral research · 2021Article
- The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors.Frontiers in microbiology · 2019Review
- Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.Antimicrobial agents and chemotherapy · 2017Article
- Prophylactic Measures During Induction for Acute Myeloid Leukemia.Current oncology reports · 2017Review
- Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity.Frontiers in microbiology · 2017Review
- Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14α-demethylase.Scientific reports · 2016Article
- Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations.Infection and drug resistance · 2016Review
- Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?International journal of nanomedicine · 2016Review
- Cutaneous mucormycosis.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isavuconazonium (Cresemba®) is a water-soluble prodrug of the triazole antifungal isavuconazole (BAL 4815), a 14-α-demethylase inhibitor, under development by Basilea Pharmaceutica International Ltd and Astellas Pharma Inc. Isavuconazonium, in both its intravenous and oral formulations, was approved for the treatment of invasive aspergillosis and invasive mucormycosis (formerly termed zygomycosis) in the US in March 2015. Isavuconazonium is under regulatory review in the EU for invasive aspergillosis and mucormycosis. It is also under phase III development worldwide for the treatment of invasive candidiasis and candidaemia. This article summarizes the milestones in the development of isavuconazonium leading to the first approval for invasive aspergillosis and mucormycosis.
Indexed as
Identifiers
25902926What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.